Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.

Phase 2

Novartis Pharmaceuticals